TNG Transgene SA

   By Inti Landauro 
 

PARIS--French pharmaceutical giant Sanofi SA (SAN.FR) said Wednesday that it will build a joint lab with partner Transgene SA (TNG.FR) to manufacture viral vectors such as MUC1, a drug developed by Transgene that targets cancer immunotherapy.

The lab will be located in Lyon and will cost EUR10 million over two years, with each company financing half the cost, Sanofi and Transgene said in a joint statement.

The two companies had announced a partnership in March last year.

Write to Inti Landauro at inti.landauro@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires